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ABSTRACT 
Children in foster care system are more likely to receive diagnoses of major mental 
illness and to be medicated with powerful medications such as antipsychotic drugs. 
Reasons for the increased risk of the actual mental illnesses and for the diagnoses of 
illness among children in foster care are reviewed. The reliabilities of various diagnoses 
are considered. The legitimacy of the rationale for early medications to prevent later 
disability is discussed. The very real hazards of medicating with antipsychotics, 
anticonvulsants, stimulants, mood stabilizers and antidepressants are reviewed. A 
discussion of advocacy efforts occurring around the United States on behalf of medicated 
children in the foster care system is presented. Finally, changes being instituted by the 
federal government through the Department of Health, Education, and Welfare and the 
Government Accounting Office (GAO),following the hearing of December 1, 2011 
convened by Senator Thomas Carper,are discussed. 
CHILDREN IN FOSTER CARE: A VULNERABLE POPULATION 
Medicating Foster Children 
In the last decade, the use of antipsychotic medications for adults and children has 
increased dramatically. Domino and Swartz (2008) compared prescriptions for antipsychotic 
medications in 1996-1997 with prescriptions for antipsychotics in 2004-2005. The rate of 
adult office visits resulting in antipsychotics rose from 0.6% to 1.3% while the rate for 
children rose from 0.2% to 0.7%. Moreover, Comer, Mojtabai, and Olfson (2011) 
documented the recent rise in the use of atypical antipsychotics to treat anxiety disorders. 
Antipsychotics are also currently being used to treat antidepressant resistant depression and 
ADHD (Crystal, Olfson, Huang, Pincus, Gerhard, 2009; Fullerton et al., 2011) and insomnia 
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(Sinaikin, 2010). The increase is especially large among children in foster care. A study of 16 
state Medicaid programs in 2007 found that 1.6% of children younger than 19 were receiving 
antipsychotics while 12.37% of children in foster care were receiving antipsychotics 
(Medicaid Medical Directors Leaning Network, 2010, p. 14). dosReis et al. (2011) examined 
psychotropic prescriptions for 16,969 children under 20 years of age in a Mid-Atlantic state 
Medicaid program. All of the children in the sample had been given a mental health 
diagnoses. For the children in foster care not awaiting adoption, 19% were being medicated 
with multiple antipsychotic drugs and 24% of children who were in foster care awaiting 
adoption were being treated with multiple antipsychotics.Similar patterns of greater use of 
psychotropic drugs of many classes were found in a number of additional studies comparing 
rates of medicating foster children to other children (Breland-Noble et al., 2004; DosReis et 
al., 2001; Raghavan et al., 2005; Raghavan and McMillen, 2008). 
Most recently, on December 1, 2011, Senator Tom Carper held a hearing to discuss the 
Government Accounting Office’s study of the psychiatric treatment of children in foster care. 
The Government Accounting Office (Kutz, 2011) issued a report on the medication of 
children in foster care in five states during 2008. Across states, children in foster care are 2.7 
to 4.5 times more likely to be medicated than children receiving Medicaid. Infants younger 
than 1 are medicated, albeit possibly with Benadryl (Salo, 2011). Doses exceeding the 
maximum levels approved by the FDA were found in several states. Across states, 0.11 to 
1.33 percent of children are being treated concurrently with over five medications. According 
to the GAO panel “our experts also said that no evidence supports the use of five or more 
psychotropic drugs in adults or children, and only limited evidence supports the use of even 
two drugs concomitantly in children (Kutz, 2011, p14).” 
Increased Risk for Mental Illness in Children in Foster Care 
Greater prevalence of a number of mental illnesses might be expected in a population of 
foster children. First, many mental illnesses have a hereditary component. Parental mental 
disorder may constitute the reason why a child is in foster care. Because a child shares 
hereditary risk with a parent, greater prevalence of particular disorders can be expected for 
children in foster care. Second, disorders such as major depression, PTSD, and anxiety 
disorders are exacerbated by stressful conditions. The National Survey of Child and 
Adolescent Well-Being finds that 70% of children in foster care have a history of child abuse 
and/or neglect, more than 80% had biological parents with impaired parenting skills, and 40% 
had witnessed domestic violence (Burns et al., 2004; Leslie, Kelleher, Burns, Landsverk, and 
Rolls, 2003; Stahmer et al., 2005). Once in the foster care system, 63% of foster children are 
placed out of home for a duration of less than two years and during those two years live in, on 
average, three different placements (US DHHS, 2007). Thus, stressful conditions prior in 
early life and unstable living situations once in the foster care system can be expected to 
exacerbate emotional problems. Third, loss of a biological parent alone can be expected to 
result in depressive and anxiety symptoms as well as Post Traumatic Stress Disorder (PTSD) 
in children. Indeed, the GAO (2011) report noted that “57% of foster children were diagnosed 
with a mental disorder—nearly 15 times that of non-foster children receiving Medicaid 
assistance.” 
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Issue of Legitimacy of Diagnosis 
In an earlier time making a correct diagnosis was important because diagnosis was a 
guide to selecting the proper treatment. However, as previously documented, currently major 
depression, ADHD, anxiety disorders, and sleep disorders are being treated with atypical 
antipsychotics. DosReis et al. (2011) found that of the foster children in their sample 
receiving an antipsychotic, 53% had a diagnosis of ADHD, 34% had a diagnosis of 
depression, 21% had a diagnosis of bipolar, while only 5% had a diagnosis of schizophrenia. 
In examining factors that contributed to the greater likelihood of receiving multiple 
antipsychotics concomitantly, being male, being African American and having diagnoses of 
conduct disorder, autism, bipolar, psychosis, and schizophrenia increased the probability. 
Many of the children in the sample being treated with antipsychotics were also receiving 
antidepressants, stimulants, and mood stabilizers. In current practice, correspondence between 
diagnoses and particular treatments no longer describes practice. DosReis et al. (2011) 
speculated regarding the rationale for using multiple antipsychotics concurrently. They 
suggested that an insufficient response to one drug might prompt the addition of a second 
drug rather than increasing the dosage of the first drug or, perhaps, adding a second drug for a 
sleep problem might have provided a rationale. They also considered that “a proportion might 
lack a reasonable clinical rationale (p.1464”). Whatever the reason, antipsychotics seem to be 
being dispensed for a wide range of diagnoses. 
While individual physicians are engaging in off-label use of various drugs such as 
antipsychotics for various diagnoses in children and adults, the Federal Drug Administration 
continues to approve drugs for particular diagnoses rather than as general purpose panaceas. 
Assuming that diagnoses are still relevant in clinical practice, two diagnostic categories, 
which are not in the DSM-IV-R but have gained a modicum of perceived legitimacy, will be 
discussed: Pediatric Bipolar and Pre-psychosis. 
Pediatric Bipolar 
Before the last decade, there was wide agreement that Bipolar Disorder did not emerge 
prior to late adolescence or young adulthood (Anthony and Scott, 1960; Goodwin and 
Jamison, 2007, p. 188; Loranger and Levine, 1978). Whereas in 1996, pediatric bipolar was 
the least frequent diagnosis in hospitalized children, by 2004, it was the most frequent 
diagnosis for hospitalized children (Blader and Carlson, 2007). How did the diagnosis of 
Pediatric Bipolar gain acceptance? In the 1990s, Joseph Biederman, a child psychiatrist at 
Harvard, and his colleagues, began publishing articles indicating that many of the children 
who were being diagnosed as having ADHD and/or conduct disorder, also met criteria for 
Bipolar Disorder (see Biederman, Mick, Faraone, Spencer, Wilens, and Wozniak, 2000; 
Biederman et al., 2003). In order to bolster his case for children actually having Bipolar 
disorder, Biederman and colleagues and others assessed the parents of those children who met 
criteria for Bipolar disorder (see review of studies in Littrell and Lyons, 2010a). Many of 
these parents also met criteria for Bipolar Spectrum diagnoses. Since Bipolar is widely 
accepted as a heritable disease, the findings in parents were purported as evidence for the 
legitimacy of the claim that these children really were bipolar and they would emerge as 
adults with Bipolar Disorder. 
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Flaws in the argument. Biederman was able to make the case that the parents of the 
children who were being diagnosed with bipolar were also bipolar because of changes in the 
DSM-IV. In 1994, the diagnosis of Bipolar II was added to the Diagnostic and Statistical 
Manual-IV of the American Psychiatric Association. In in the 1994 manual and the current 
2000 version of the manual, whereas a diagnosis of Bipolar I requires that a patient meet 
criteria for an episode of mania, a diagnosis of Bipolar II only requires meeting criteria for 
hypomania. The same behaviors are listed for both mania and hypomania. The difference is 
that mania must last for a week whereas only four days are required for hypomania and, most 
importantly, if the behaviors result in functional impairment, then the diagnosis of mania is 
given rather than hypomania (see DSM-IV-TR, 2000, p. 368). The fact that hypomania does 
not result in significant functional impairment (DSM-IV-R) and the fact that hypomania is 
very common in the general population (Udachina and Mansell, 2007; Wicki and Angst, 
1991) augured that the diagnosis of Bipolar would sky-rocket. Indeed, Moreno, Laje, Blanco, 
Jiang, Schmidt, and Olfson (2007) have documented a 38% increase in adult bipolar 
diagnoses from 2002-2003 compared to 1994-1995. 
The problem with the diagnoses of Bipolar I and Bipolar II is they are two distinct 
disorders. In an early study, tracking those with Bipolar II diagnoses over time found that 
they were very unlikely to meet criteria for mania in later life (Coryell et al., 1995). Studies 
examining the family members of those with Bipolar I and Bipolar II, established that 
relatives of those with Bipolar I, for the most part, met criteria for Bipolar I and relatives of 
those with Bipolar II, for the most part, met criteria for Bipolar II (e.g., Coryell et al., 1984; 
see Littrell and Lyons, 2010a for review).  The alleles for various genes increasing the risk for 
Bipolar I are not shared by those with Bipolar II (Judd et al., 2003; Vieta and Suppes, 2008). 
Moreover, distinct trajectories describe the course of the two disorders over time (Judd et al., 
2003). Thus, the common label “bipolar” for those meeting criteria for Bipolar I and Bipolar 
II is very misleading.  
In the studies examining the parents of children with Pediatric Bipolar, researchers failed 
to distinguish whether the parents met criteria for Bipolar I or Bipolar II (Littrell and Lyons, 
2010a). Thus, the inference that children meeting criteria for Pediatric Bipolar had a genetic 
predisposition for Bipolar Disorder I based on the findings from studies of their parents was 
not legitimate and very misleading. 
There were additional reasons for questioning whether children being diagnosed as 
Pediatric Bipolar would ever become Bipolar I adults. Many retrospective studies of adults 
with well-characterized Bipolar I suggested that they had exhibited depressive symptoms but 
not mania symptoms as children. For most adults with Bipolar I, a diagnosis of Major 
Depression preceded the emergence of mania. Moreover, there were a number of longitudinal 
studies of the children of parents with well characterized Bipolar I Disorder. Typical of these 
studies is work of Anne Duffy and colleagues. In a recent publication, Duffy, Alda, Hajek, 
and Grof (2009) reported that in their now young adult children of parents with Bipolar I, 
mania never emerged prior to 12, the mean age for the emergence of mania was 17, and in 
those in whom mania emerged, it was most often presaged by depressive symptoms in 
childhood. Thus, the children being diagnosed with Pediatric Bipolar, whose behavior 
overlapped with Attention Deficit/Hyperactivity, were obviously from a different population. 
(See Littrell and Lyons, 2010a, for citations and a review of the material referred to in this 
section.) 
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While psychiatrists are employing the Pediatric Bipolar diagnosis with great regularity, 
the various Committees established to develop diagnoses for children in the forthcoming 
DSM-V report are considering diagnoses of Temper Dysregulation Disorder with Dysphoria 
and Severe Mood Dysregulation (DSM-V Mood Disorders Workgroup; DSM-V Childhood 
and Adolescent Disorder Work Group, 2011) to supplant the Pediatric Bipolar label. Both 
antidepressants and stimulants can precipitate manic behavior (Delbello et al., 2001; Ghaemi, 
Hsu, Soldani, and Goodwin, 2003; Martin et al., 2004; Spetie and Arnold, 2007). The 
workgroups have noted that alternative terminology, a mere change in wording, could reopen 
the question of appropriate treatment for children currently being labeled Pediatric Bipolar. 
The committee recognized that for persons to whom the label “bipolar” is applied, “current 
convention renders treatment with antidepressants or stimulants relatively contraindicated 
without concurrent mood stabilizers or antipsychotics, (p. 6).” The discussions of the DSM-V 
workgroups reveal the degree to which confusion reigns as to how to identify legitimate 
diagnoses and what constitutes good treatment. 
Pre-Psychosis 
Considerable research has focused on the identification of markers that presage the 
development of psychosis. The hope was to be able to intervene early in the process and 
prevent schizophrenia. Allen Frances (2010b; 2011c), Co-Chair of the DSM-IV, articulates 
his objection to Pre-Psychosis in the forthcoming DSM-V. He argues that predictors of 
psychosis are not yet sensitive or specific. Indeed, Thompson, Nelson, and Yung (2011), 
developers of criteria for predicting future psychosis, reported that only 64.5% of those who 
developed schizophrenia were identified by their battery and for those scoring high, 35% 
were false positives. Examining persons in the high risk category, only 39.4% transitioned to 
psychosis during the 28 month follow-up interval. Thus, even given the best tools for 
identifying persons who will become psychotic, false positives are high. Allen Frances argues 
that given the state of the art, labeling children as “pre-psychotic” would not only be 
stigmatizing but would also result in unneeded medications. 
Post Traumatic Stress Disorder 
Many of the symptoms exhibited by children in foster care who are being medicated 
overlap with symptoms of PTSD. Hyper-alertness, irritability, and emotionality have been 
noted in Veterans returning from Iraq (Tyre, 2004). Thus, behavioral disturbance can be 
expected in those suffering trauma. Certainly, all children in foster care meet criteria for 
trauma: all have been removed from their biological families. Presently, reliable methods for 
distinguishing responses to trauma from other disorders in children have not been proffered. It 
is notable that the American Academy of Child and Adolescent Psychiatry (Gleason et al., 
2007) specifically advises that PTSD in children should be treated with talk therapy and 
should not be medicated. 
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CAN EARLY PHARMACOLOGICAL INTERVENTION 
Change the Course of a Disorder? 
Bipolar 
Kiki Chang and colleagues (2010; Chang, Howe, Galleli, and Miklowitz, 2006; Chang 
and Kowatch, 2007) have been proponents of the idea that early pharmaceutical treatment of 
Bipolar Disorder can prevent the emergence of severe symptoms. For his rationale, Chang 
references the kindling theory proffered by Robert Post (2007). The kindling theory posits 
that some process occurs in the brain when individuals are symptomatic which alters the 
physical characteristics so that severe symptoms are easier to elicit afterwards. If symptoms 
can be blocked, the kindling process can be precluded and the brain will remain healthy. That 
is the theory. Do the data support the theory? 
In his many publications Chang fails to acknowledge some relevant facts. First, Goodwin 
and Jamison (2007), in their classic work on Bipolar, find little evidence for the kindling 
hypothesis that greater initial symptoms play a causal role in creating later symptoms (see 
Goodwin and Jamison, 2007, p. 152). With regard to early treatment changing the course of 
the disorder, Baldessarinni and colleagues have examined the impact of early treatment on the 
course of the Bipolar disorder and conclude that early treatment has no impact on subsequent 
frequency or severity of mood episodes (Baethge et al., 2003; Baldessarini, Tondo, Baethge, 
and Bratti, 2007). Finally, in Post’s research on kindling which involved inducing seizure 
activity in rodents, suppression of seizures with anticonvulsants did not alter later sensitivity 
to provoking seizures, in fact, lamotrigine and carbamazine facilitated kindling (Post, 2004; 
Weiss, Clark, Rosen, Smith, and Post, 1995; Postma, Krupp, Li, Post, and Weiss, 2000). 
Thus, the logic behind the rationale for early treatment is not supported by the facts. As we 
will be discussed in a later section, all of the drugs for Bipolar have severe deleterious effects 
on health. Thus, delaying treatment as long as possible seems a worthy goal. 
While evidence is lacking for early treatment altering long term outcome, Whitaker 
(2010) has questioned whether pharmacological interventions for Bipolar I in adults, in fact, 
impairs long term outcome. Although drugs are approved by the FDA on the basis of 
evidence of efficacy, it should be noted that drug efficacy studies observe patients for about 
eight weeks. There have been no studies with random assignment to treatment and placebo 
with long term follow-up over years. An early naturalistic study with a ten year follow-up by 
Winokur et al. (1994) concluded that medications were not significantly related to outcome 
for patients with Bipolar.  
Without the availability of random control studies to assess long term outcome of 
treatment, one can contrast the pre-drug literature on outcomes for Bipolar Disorder with 
current long term studies.This is what Whitaker did in his book. With regard to evaluation of 
patients before drugs, Rennie (1942) found that 93% of patients with mania recovered from 
their initial episode in an average of several months. Twenty-one percent never relapsed. Of 
those who did relapse, 30% remained remitted for at least 10 years with an average duration 
of remission of 20 years. Thus, after an initial period of bipolar symptoms, 51% were 
remaining well for a significant period of time. Later studies of those with Bipolar I in the 
post drug era find that only 2.1% of persons are asymptomatic during a 12.8 year follow-up; 
80% of those who recover relapse within 1.7 years; 23% are continuously unemployed and 
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another 35% are erratically employed (Harrow, Goldberg, Grossman, and Meltzer, 1990; 
Judd et al., 2002). Examining outcomes for those with Bipolar II, Judd et al. (2003) 
concluded that Bipolar II is an even more chronic condition than Bipolar I. 
Psychiatrists have also provided global assessments of outcomes for Bipolar Disorder. A 
review of early studies prompted Winokur, Clayton, and Reich (1969) to conclude there “was 
no basis to consider manic depressive psychosis permanently affected those who suffered 
from it” (p.21). This contrasts with the dismal prognosis, provided by the Judd et al. (2002) 
findings in the longest follow-up study of medicated patients in the post-drug literature 
discussed previously. Zarate, Tohen, Land, and Cavanagh (2000) have also noted the contrast 
between earlier and current outcomes: “In the era prior to pharmacotherapy, poor outcome in 
mania was considered a relatively rare occurrence. However, modern outcome studies have 
found that a majority of patients with bipolar evidence high rates of functional impairment” 
(p. 309). The contrast between early conclusions on Bipolar Disorder with current outcome 
studies should have prompted the hypothesis that drugs create a worse outcome. Rather, the 
conclusion made by psychiatrists is that in modern times we conduct more sensitive research 
and thus can develop more realistic expectations of prognosis. 
It should be noted that the efficacy of lithium for reducing bipolar symptoms in children 
ages 7-17 has been called into question (Dickstein et al., 2008). 
Pre-Psychosis and Psychosis 
In examining efficacy of early medicating of psychosis, two types of studies can be 
examined. The first literature considers studies asking whether early treatment for those 
exhibiting overt psychosis changes the long term outcome of the later course of psychosis. 
Most of the studies in this literature were on young adults and not children. Indeed, in a meta-
analysis by Perkins et al. (2005), the mean age of those with first episode psychosis was 27.8, 
so direct relevance to children can be questioned. However, this literature does shed light on 
the effects of early treatment. Another set of studies has examined the impact of treatment 
intervention on those who only exhibit symptoms believed to be predictive of later psychosis 
and who may have relatives with psychosis. The issue of the efficacy of early treatment of 
those already exhibiting psychotic symptoms, for psychosis and the issue of preventing 
psychosis are examined separately. 
Treating overt psychosis early. Two large meta-analysis (Marshall et al., 2005; Perkins, 
Gu, Boteva, and Lieberman, 2005) have concluded that in those individuals exhibiting 
delusional thinking or experiencing hallucinations, delaying treatment is associated with more 
negative outcome. However, both of these reviews identified significant caveats in drawing 
the conclusion that early treatment causes better outcome. In both the Perkins et al. and 
Marshall et al. reviews, those receiving delays in treatment were distinguished by greater 
negative symptoms. Some of the positive benefit of early treatment was attenuated after 
controlling for initial characteristics. Moreover, in both reviews difference in outcome 
between those receiving early and late treatment was modest, with Perkins noting that delay 
in treatment accounted for only 13% of the variance in outcome. 
Preventing the emergence of psychosis. A number of investigators have evaluated 
interventions to reduce the transition to psychosis in samples selected for high risk. No clear 
benefit for psychotherapy, family interventions, or antipsychotic drugs was apparent 
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according to a review conducted by the Cocharane Collaboration (Marshall andRathbone, 
2011a, b). However, there was a suggestive positive result from the use of omega-3 fatty acid 
supplements. In a study by Amminger et al. (2010), 81 high risk subjects were randomly 
assigned to take omega-3s or placebo. They were evaluated on global functioning and level of 
symptoms at 52 weeks. Some of the patients in the omega-3 group and the control group were 
taking benzodiazepines or antidepressants but none were taking antipsychotics. By 52 weeks, 
4.9% of the omega-3 group and 27.5% of the placebo group had transitioned to psychotic 
disorder (Amminger et al., 2010). Along with the just-cited suggestive evidence for efficacy 
of omega-3 in preventing the emergence of psychosis, there is evidence that omega-3 have 
strong antidepressant properties (Kiecolt-Glaser, 2010). Moreover, in a study of medical 
students, omega-3 supplementation did attenuate symptoms of stress (Kiecolt-Glaser, Belury, 
Andridge, Malarkey, and Glaser, 2011). Omega-3s are found in fish and walnuts. Dietary 
supplements are also available. 
ADHD 
Years ago, Judith Rappoport and colleagues (Sostek, Buchsbaum, and Rapoport, 1980) 
conducted a study in which she gave stimulants to all the children, both those with ADHD 
and those without. She found that attention and vigilance improved for all children 
administered the stimulant. Stimulants are noted for focusing attention and enhancing 
memory formation in adults (Hart, Ksir, and Ray, 2009; Soetens, D’Hooge, Huesting, 1993). 
Studies evaluating improvement in school performance, do find that children with ADHD do 
better with stimulants. However, the results of the Multisite Multimodal Treatment Study 
(MTA) shed light on long term outcomes. In this study, outcomes for children with ADHD 
who had never been medicated were contrasted with those who had been medicated, some of 
whom were continuing with medications and others who were not. In the long run over eight 
years, children with ADHD on drugs versus children never on drugs show no difference in 
resultson school achievement. For the MTA study, Molina et al. (2009) noted even those who 
continued taking medications did not differ from the non-medicated on most measures, with 
the exception of some benefit for continued drug use on math performance. 
Major Depression 
The acknowledged fact, even among psychiatrists, is that antidepressants do not work 
very well even during the eight weeks of initial treatment in adults. Only two-thirds of 
patients respond to a trial of antidepressant (Thase et al., 2005; Tratner, O’Donovan, 
Chandarana, and Kennedy, 2002). One half of responders are acknowledged to be placebo 
responders. Of those who respond to drug, less than half achieve remission from depression 
(Calabrese et al. 2006; Nemeroff, 2001; Tratner et al. 2002). The previous statements are 
based on published studies in which the results of treated versus controls did reach statistical 
significance.  
Small reliable differences can be detected when the sample sizes are large enough. On the 
other hand, in order to be able to recognize when occasionally observed differences are 
merely chance, and there is in fact no effect, all data must be entered. If some studies which 
do not show effects are excluded, then there is an increased likelihood that false statistical 
evidence of effects (particularly small effects) can appear among remaining studies. Irving 
Kirsch (2010) gathered all the data from antidepressant studies comparing drug to placebo 
that were reported to the FDA by the drug companies. Analyzing this more complete set of 
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the comparisons between drug and placebo groups, the statistical conclusion was that there 
was little difference between the groups. The average difference between those treated with 
an antidepressant versus those receiving placebo is 2 points out of 51 points on the Hamilton 
Rating Scale, a commonly used assessment measure (Kirsch, Moore, Scoboria, and Nichols, 
2002). These results may have contributed to the recent remark by the current director of the 
National Institute of Mental Health,Thomas Insel (2009), who offered a bottom line on the 
effectiveness of psychotropic medications in general, when he said: “The unfortunate reality 
is that current medications help too few people to get better and very few people to get well” 
(p. 704). 
Whereas efficacy of the antidepressants even in the short term is questionable, others 
have examined the long term outcomes on depression for those taking antidepressants 
contrasted with outcomes for depression in the pre-drug literature. Giovanni Fava (2003) was 
an early pioneer in this endeavor. He advanced the hypothesis that current treatments convert 
an acute problem into a disorder with a chronic course. Fava and Offidani (2011) reported a 
similar argument. Littrell (1994) also contrasted outcomes for depression prior to drugs and 
noted the same pattern of more frequent relapses in those treated with drugs. A recent 
evaluation by Andrews, Kornstein, Halberstadt, Gardner, and Neale, M. C. (2011) of 
outcomes with antidepressants compared to the depressed but unmedicated reached a similar 
conclusion. Although the explanations provided for the greater number of relapses over the 
long run in those taking antidepressants contrasted with those who do not have varied, the 
worse outcomes in those with drugs has been acknowledged by those who have looked at the 
data. Littrell (1994) offered drug withdrawal as an explanation for the high rate of depressive 
symptoms observed in those discontinuing antidepressant medications. Depressive symptoms 
emerge upon drug discontinuation even in those who were taking antidepressants for anxiety 
symptoms and who had not been previously depressed (Pato, Zohar-Kadouch, Zohar, and 
Murphy, 1988).  
The efficacy of antidepressant drugs is particularly suspect for children and adolescents. 
Jureidini et al. (2004) conducted a meta-analysis of the six published randomized controlled 
studies they could find in the literature evaluating new antidepressants. According to the 
authors “On 42 reported measures, only 14 showed a statistical advantage for an 
antidepressant. None of the 10 measures relying on patient reported or parent reported 
outcomes showed significant advantage for an antidepressant, so that claims for effectiveness 
were based entirely on ratings by doctors (p. 880)”. Two small studies did not find statistical 
significance. Among the larger studies, two found significant advantage, while two did not. 
With regard to effect sizes in the positive studies, “the effect size of 0.26 is equivalent to a 
very modest 3 to 4 point difference on the scale, which has a range of possible scores from 17 
to 113 (p. 880).”Thus, the magnitude of the difference between antidepressant treated 
children’s group versus placebo is very small, similar to published results in adults. 
Consistent with the unclear evidence of efficacy for antidepressants in children, Goodman, 
Murphy, and Storch (2007) noted that in only 3 of 15 outcome studies submitted to the FDA 
examining antidepressant efficacy in children for antidepressants were results significant. It 
should be noted that only fluoxetine/Prozac has been approved by the FDA for treating 
depression in children, although Prozac, Zoloft/sertraline, and fluvoxamine are approved for 
treatment of obsessive compulsive disorder. 
The largest study of antidepressants in children was the “Treatment of Adolescents with 
Depression Study” which involved 13 academic centers and 327 adolescents ages 12 to 17 
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randomly assigned to Cognitive Behavioral Therapy, fluoxetine/Prozac, or a combination. At 
12 weeks 73% had experienced a 50% drop in symptoms with combination therapy, 
compared to 62% with fluoxetine alone, and 48% with CBT. However, by 18 weeks, 
differences between CBT and fluoxetine were no longer significant. By 24 weeks, differences 
among treatments were no longer significant on percentages responding to treatment. By 24 
weeks, approximately 89% could be counted as responders. In terms of relapses during the 36 
months among those who were categorized as responders at 12 weeks, CBT had 3.1% 
relapses compared to 25.9% relapses in the Prozac group, and 11.5% relapses in the 
combination group (Rohde et al., 2008). At one year, a point when the researcher did not 
know what treatments the participants were receiving, a lack of difference among the groups 
remained. 82.2% of the combined group, 75.2% of the Prozac group, and 70.3% of the CBT 
group were categorized as responders defined as a 50% drop on scale scores. Recall that 
responding is not the same as being well. At one year, in terms of those who could be said to 
be well: 68% of the combined group, 67% of the Prozac, and 69% of the CBT group were 
described as remitted/well(TADS Team, 2009).  
Suicidal events, defined as a suicide attempt, suicidal ideation, or preparatory action 
toward suicide, but not self-mutilation, were also measured in the TAD study. There were 
significantly more suicidal events during the 36 weeks with Prozac (14.7%) than with 
combination (8.4%) or than with CBT (6.3%) (TADS Team, 2007). For newly emergent 
suicidal events at 12 weeks, the interval during which most of the suicidal events occurred, 
the numbers were: 11.0% for Prozac; 4.7% for combination; 4.5% for CBT (TADS Team, 
2007). Thus, the more rapid response to treatment with Prozac is offset by an increase in the 
risk for suicidal events. 
DANGERS OF MEDICATIONS 
Anti-Psychotics 
Probably the worst side effect of drugs which block the action of dopamine is “brain 
tissue volume decrement.”Ho, Andreasen, Ziebell, Pierson, and Magnotta (2011)tracked first-
episode psychotic individuals over an average of seven years. They took brain images over 
time. They documented a decrease in brain volume that was associated with the dosage of the 
medication. The effects obtained for both the older (neuroleptics) and the new (atypical) anti-
dopaminergic drugs. Ho et al. acknowledged that because they did not observe random 
assignment to a control group of non-medicated individuals, they could not make a definitive 
statement that the drugs caused the brain volume decrement. It could have been that those 
receiving the higher dosages did not come from the same population of individuals. However, 
Ho et al. cited research with primates. Konopaske et al. (2007; 2008) randomly assigned 
primates to receive anti-dopaminergic drugs at levels in the therapeutic range for people for 
27 months. Those animals who received the drugs exhibited a reduction in total weight of the 
brain, with greatest reduction in the parietal lobe (with a loss of between 11.8% to 15.2%). 
Moreover, a 14.2% reduction in glial cell (fat cells) numbers was reported. The glial cell 
reduction is notable because these cells release growth factors which are vital to maintain the 
health of the brain (Schwartz and Schechter, 2011; Ziv and Schwartz, 2008). Dopamine, the 
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neurotransmitter blocked by antipsychotic drugs, is a trigger for getting glial cells to release 
growth factors (Miklic, Juric, Carman-Krzan, 2004). The Konopaske studies are not the only 
studies in primates. Results similar to Konopaske et al.’s were found in a macaque study by 
Dorph-Petersen et al. (2005) who noted a 8-11% reduction in brain volume after 1.5 to 2.3 
years of exposure to haloperidol (old neuroleptic) or olanzapine (new atypical). 
While brain volume reduction may be the most ominous side-effect of the antipsychotic 
drugs, brain volume reduction is not the only side effect. Atypical antipsychotics are 
notorious for inducing weight gain that does not plateau, type-2 diabetes, and an increase in 
fat levels in blood. Children are at elevated risk for developing metabolic side effects (Correll 
and Carlson, 2006; Safer, 2004; Sikich et al., 2004; Tohen et al., 2007; Woods et al., 2002). 
The older neuroleptic drugs have long been noted to be associated with Parkinson’s 
symptoms (extra-pyramidal symptoms) in the short term, and permanent movement disorders 
(tardive dyskinesia) in the long run. The Clinical Antipsychotic Trial of Effectiveness study, a 
big government funded study, found that newer drugs were also associated with movement 
disorders, albeit to a lesser extent (Casey, 2006; Manschrek and Boshers, 2007; Miller et al., 
2005). The FDA has also issued a warning indicating that the atypicals are associated with 
QT wave prolongation. Thus, fatal heart arrhythmias can occur (Psychiatric News Alert, 
2011). Atypicals are also associated with lowered bone mineral density (Calarge, 
Zimmerman, Xia, Kuperman, and Schiechte, 2010). 
Lithium 
Lithium causes cognitive slowing in adults (Ghaemi, 2008; Pachet and Wisniewski, 
2003); impairment is also observed in children (Geller et al., 1998; Silva, 1992). Other 
annoying side effects include: confusion, slurred speech, ataxia, frequent urination, enuresis, 
abdominal discomfort, nausea, and vomiting (Hagino et al., 1995). Twenty percent of patients 
experience weight gain (Chen and Silverstone, 1990). Lithium is associated with thyroid 
dysfunction (Goodwin and Jamison, 2007). Lithium can cause damage to the cerebellum 
(Goodwin and Jamison, 2007) and has been associated with cardiac arrhythmias (Ghamei, 
2008). 
Perhaps most troubling for medicating children is the risk of End Stage Renal Disease in 
those treated for an extended period of time (over 12 years). In a sample of 74 patients treated 
for 20 years, 12 reached End Stage Renal Disease (Presne et al., 2003). Presne noted that fifty 
percent of patients on lithium exhibit impaired renal concentrating ability (Presne et al., 
2003). Even when medication is discontinued, kidney damage once started can continue 
(Markowitz et al., 2000), although kidney damage is related to the duration of lithium 
treatment (Bendz, Aurell, and Lanke, 2001). Extrapolating from these finding, if children are 
placed on lithium at age 6, some of them will need a kidney transplant at age 26. People 
develop an immune response to their transplants even when on immunosuppressants 
(Galliford and Game, 2009). Approximately, 19% of kidney transplants will be rejected 
within five years (Murphy, 2010, p. 259). Thus, lithium treatment in children can be expected 
to significantly shorten life span for some, if not many, of them. 
Mood Stabilizers 
The annoying side effects of valproate include sedation, nausea, and vomiting. 
Hematological side effects (anemia, low white counts) have been noted (American Academy 
of Child and Adolescent Psychiatry, 1997). Up to 89% of young women treated with 
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valproate develop polycystic ovarian disease, involving weight gain, facial hair, and 
menstrual irregularities (Isojarvi et al., 1993). Valporate increases risk for diabetes (Correll 
and Carlson, 2006). Both hepatitis and pancreatitis can be induced by valproate and carry 
black box warnings issued by the FDA (2009) 
Depression can be induced and both carbamazepine and valproate have black box 
warnings for suicidal ideations (US FDA, 2008). Anticonvulsants such as valoporate are 
noted for inducing cognitive impairment (American Academy of Child and Adolescent 
Psychiatry, 1997; Banu et al., 2007; Loring and Meador, 2004Henin et al., 2009). 
Lamotrigene is another mood stabilizer. Lamotrigene is associated with Stevens-Johnson 
syndrome. Stevens-Johnson’s syndrome entails life threatening blistering on all external body 
surfaces (Borchers, Lee, Naguwa, Cheema, and Gershwin, 2008). 
Stimulants 
Stimulants include amphetamines and Ritalin/methylphenidate. Adderall is a long acting 
form of amphetamines, while concerta is a timed-release preparation of Ritalin. 
Stimulantshave a black box warning for heart attacks in Canada and the U.S. (CanWestNews, 
2008; Physician’s Desk Reference, 2012). Stimulants do suppress growth in height possibly 
through inhibition of growth hormone (Faraone, Biederman, Morley, Spencer, 2008; Zhang, 
Du, Zhuang, 2010).  
Stimulants can induce psychosis and are associated with sleep disturbance and 
suppression of appetite, and induction of motor tics (Physician’s Desk Reference, 2012). 
Stimulants also suppress playfulness in animals (Beatty, Dodge, Dodge, White, and 
Panksepp, 1982) . Animal research suggests that the purpose of play in youngsters, which is 
found cross species, is to facilitate social development and maturation of the orbitofrontal 
cortex and the Prefrontal Cortex (Bell, Pellis, and Kolb, 2010). Most of the research on 
stimulants has focused on the impact on concentration and school performance. Very little 
research has focused on social development. It is, however, known that stimulants can 
precipitate mania in the predisposed (DelBello et al., 2001). 
As a part of the Individuals with Disabilities Education and Improvement Act of 2004, 
Schools cannot require children to take a stimulant to stay in school (see AbleChild.org web 
site). 
Anti-Depressants 
Selective Serotonin Reuptake Inhibitors carry black box warnings for agitation and 
suicidal ideation in children and adolescents (US FDA, 2007). Reinblatt, doReis, Walkup, and 
Riddle (2009) document that the SSRI, fluvoxamine, will induce “activation adverse events” 
including increased activity, impulsivity, insomnia, and disinhibition, in 45% of children. In 
adults, loss of libido and sexual dysfunction are common (Rosen, Lane, Menza, 1999). 
Studies examining the impact of SSRIs on puberty and or later adult sexual functioning are 
not available, although in adults sexual dysfunction can persist after drug discontinuation 
(Csoka, Bahrich, Mehtonan, 2008). Studies with adults suggest that taking antidepressants for 
over a year is associated with weight gain (Fava, 2000; Raeder et al. 2006); an increase in C-
Reactive Protein, a risk factor for cardiovascular disease(Hamer et al., 2011); type II diabetes 
(Kivimäjum et al., 2010; Raeder et al., 2006;Rubin et al., 2010); and metabolic syndrome 
(Dawood et al., 2007; Kemp et al., 2010); and cognitive impairment (Damsa et al., 2004; 
Fava, 2006). Brain imaging research investigating the emotional numbing effect of selective 
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serotonin reuptake inhibitors (SSRIs), finds that in persons taking SSRIs emotional response 
to both positive and negative stimuli are dampened (McCabe, Mishor, Cowen, and Hamer, 
2010). Several studies have found that SSRIs are associated with suppression of growth 
hormone and suppression of growth (Weintrob, Cohen, Klipper-Aurbach, Zadik, and 
Dickerman, 2002) as well as decreased bone mineral density (Calarge, Zimmerman, Xie, 
Kuperman, and Schlechte, 2010). 
A major problem with initiating treatment with antidepressants is that they are associated 
with severe withdrawal symptoms when the drug is discontinued. As previously discussed, 
depression emerges as a component of withdrawal even in those who were taking 
antidepressants for anxiety and were not initially depressed (Pato, Zohar-Kadouch, Zohar, and 
Murphy, 1988). Haddad (1997) indicates that 20-86% of sample report symptoms, after 
discontinuing the drug, which include dizziness, nausea, lethargy, headache, anxiety, tingling 
and burning sensations, confusion, tremor, sweating, insomnia, irritability, memory problems, 
anorexia. Stoukides and and Stoukides (1991) provided a case report of man who had taken 
Prozac/fluoxetine for 6 months. Upon discontinuation, the man experienced muscle spasms 
and exhibited protruding tongue movements. Consistent with the case report, Ceccherini-Nelli 
et al. (1993) reported that of 10 individuals examined, seven exhibited withdrawal symptoms 
which included cardiac arrhythmia, resting tremor of the jaw, tongue, and upper extremities, 
insomnia, chills, sweating, nausea, headache. Along with other symptoms, Lejoyeux and 
Adés (1997) reported mania or hypomania, delirium, mood changes, dizziness, sensations of 
tingling and burning in limbs. Goldstein et al. (1999) and McGrath et al. (1993) also reported 
the emergence of mania upon withdrawal. Surprisingly, protocols for detoxing patients from 
antidepressants have not been published.  
Assuming female foster children will grow up and have normal lives including becoming 
parents themselves, continuing with SSRIs during pregnancy is problematic. SSRIs increase 
the risk of autism (Croen, Grether, Yoshida, Odouli, and Hendrick, 2011) and decreased head 
circumference (Marroun et al., 2012). Withdrawal symptoms in the infant, heart defects, 
hypospadias (misplaced urethra opening in the male), and life threatening pulmonary 
hypertension in the new born have been reported for infants exposed to antidepressants during 
gestation (Chambers et al., 2006; Gentile, 2011; Udechuku, Nguyen, Hill, and Szego, 2010). 
Antidepressants also increase the risk for hypertension in the mother during pregnancy (Anick 
Berard 2012 British Journal of Clinical Pharmacology).  
Research on Bipolar I has documented that early onset depression is often a precursor to 
the emergence of mania (Leverich et al., 2006). Thus, depression in a child is a risk factor for 
mania. Indeed, Goldberg et al. (2001) found that 19% of their young depressives converted to 
mania. It is further known that antidepressants can precipitate a mania (Ghaemi, Hsu, Soldani, 
and Goodwin, 2003). Indeed, antidepressants can precipitate mania in as many as 44% of 
those who exhibit fluctuations in mood (Akiskal, Djenderedijian, Rosenthal, andKhani, 
1977). Thus, the relatively high risk of inducing mania is another danger of using 
antidepressant medications in young persons. 
FORCES BEHIND DIAGNOSING AND MEDICATING CHILDREN 
At the individual level, some of the incentive for providing strong diagnoses to children 
derives from the Medicaid system allowing more visits to those children with more extreme 
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diagnoses. Moreover, severe diagnoses may qualify a child for Supplemental Security Income 
from the Social Security System. Once particular diagnoses are provided, medication seems 
to follow automatically despite the guidelines of the American Academy of Child and 
Adolescent Psychiatry (Gleason et al., 2007) that for small children, other interventions 
should be tried first. The pressures toward diagnosis cannot, however, explain the higher 
doses of medications exceeding recommendations of the FDA and why so many children 
received multiple medications. Perhaps one has to look at how doctors are trained and to the 
financial ties to the pharmaceutical industry of the academic opinion leaders who are running 
the continuing education programs.  
Senator Charles Grassley’s committee investigated the ties between academic 
psychiatrists and the pharmaceutical industry. Both Charles Nemeroff of Emory University 
and Joseph Biederman of Harvard were sanctioned for failing to reveal the extent of their 
financial remuneration to their employers (Harris and Carey, 2008a/b). (Biederman, as 
mentioned previously, was the exponent for the diagnosis of Pediatric Bipolar.) In the 
Grassley Committee hearings, there was also concern expressed over the ghostwriting of 
articles and books by the pharmaceutical industry with prominent academicians appending 
their names to these publications (Grassley, 2010).. 
Notes of caution against the broad based use of antipsychotics have appeared in the 
literature. For example, Ho et al. (2011) indicate “our findings may lead to heightened 
concerns regarding potential brain volume changes associated with the sharp rise in atypical 
antipsychotic use in non-schizophrenic psychiatric disorders (p. 135).” Dos reis et al. (2011) 
caution, “Antipsychotic poly-pharmacy has demonstrated greater adverse effects with only 
marginal benefits” and “Given the lack of scientific evidence for such practice, the lack of 
data on the cumulative risks on child development, and the clear indications of the metabolic 
adverse effects with these agents, it is important to investigate concomitant antipsychotic use 
in this vulnerable child population.” Comer, Mojtabai, and Olfson (2011), referring to the rise 
of atypicals in the treatment of anxiety disorders, indicate “Prudence further suggests that 
renewed clinical efforts should be made to limit use of these medications to clearly justifiable 
circumstances (p. 1064)”. However, the words of caution provided in the journals may not be 
enough to drown out advertisements from pharmaceutical houses and the cacophony of 
opinion leaders tethered to industry.  
There is a problem with the system for informing physicians. Doctors do have to 
accumulate continuing education hours to maintain their licenses. There is no formal 
mechanism for awarding credit for simply reading journals. Drug companies sponsor and 
select the speakers for the Continuing Education Programs. All the medical journals are 
replete with industry advertisements. Given the system for informing doctors, it is no wonder 
why many physicians, who were writing prescriptions for poly-pharmacy and dosages in 
excess of those recommended by the FDA, probably believed that they were following good 
practice. 
ALARM AND ADVOCACY 
Presently, Allen Frances (2009; 2010a/b), a Co-Chair of the DSM-IV, has led a rebellion 
against the Committees developing the DSM-V. Frances cautioned against the unintended 
consequences of the manner in which the DSM-IV criteria were stated, which led to the 
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epidemic rise in the diagnoses for ADHD and Bipolar Disorder (Frances, 2011c). In an 
interview with Gary Greenberg (2010), Allen Frances explained his activism, “kids getting 
unneeded antipsychotics that would make them gain 12 pounds in 12 weeks hit me in the gut. 
It was uniquely my job and my duty to protect them. If not me to correct it, who? I was stuck 
without an excuse to convince myself.” A petition, entitled “Open letter to the DSM-5”, on 
October 23, 2011, launched by the Society for Humanistic Psychology and several other 
American Psychological Association divisions, was posted on the Web 
(http://www.ipetitions.com/petition/dsm5/). The petition implores the DSM-5 committees to 
avoid further loosening of the criteria for being diagnosed with a mental disorder. Frances 
(2011a, b) has applauded the effort and has urged others to sign. 
A number of physicians have written books detailing how the industry has provided 
lucrative fees to academic opinion leaders who present the materials carefully prepared by the 
pharmaceutical industry at continuing “education” conferences. Carl Elliott (2010) in White 
Coat, Black Hat details the lack of ethics in medicine generally and the heavy domination by 
pharmaceutical houses. Doug Bremner, an Emory psychiatrist who was once an opinion 
leader on the circuit marketing pharmaceuticals, has a web site where he discusses the side 
effects of various medications. Doug Bremner (2011), in the Goose that Laid the Golden Egg 
as well as on his website, details his legal entanglements with drug companies when he 
published a study connecting Accutane, a drug used in the treatment of acne, with increased 
risk for suicide. Phillip Sinaikin (2010), another individual once on the circuit for the 
pharmaceuticals, offers witness testimony to corruption of influential members of the 
psychiatric profession in Psychiatryland. Joanna Moncrieff (2003) also detailed the influence 
of the pharmaceutical industry in “Is psychiatry for sale?” Marcia Angell (2005), former 
editor of the New England Journal of Medicine, has written extensively about loss of 
credibility in the medical profession because of ties to industry. Recently, she (2011) offered 
a supportive review of Bob Whitaker’s (2010) Anatomy of an Epidemic in New York Review 
of Books. (Whitaker contrasts outcome pre and post drugs for anitdepressants, mood 
stabilizers, and antipsychotics and finds that outcomes are worse with drugs.) She concurs 
that there is a paucity of data on the long term effects of psychotropic medications of any type 
for any age. Most of the “data” consists of industry funded studies which follow patients for 
eight weeks. 
Others have focused more specifically on the heavy medications being used for foster 
children. The public broadcasting system program The Watchlist (2011) aired “The 
Medication of Foster Children”. Diane Sawyer ran segments on ABC news documenting the 
medication of children in foster care during the first week in December of 2011. Jeffery 
Thompson, a state Medicaid director in Washington state, organized the Medicaid Medical 
Directors Learning Network (2010) to investigate the practice of medicating foster children 
with strong medications. Senators Grassley and Landrieu developed the Senate Caucus on 
Foster Care Youth to investigate the issue of psychotropics (Samuels, 2011). James Gottstein 
of Psychrights sued the state of Alaska on behalf of foster children. Senator Carper of 
Delaware held a Committee meeting on December 1, 2011 to hear testimony of experts and to 
discuss the findings of the GAO on the five state survey on the extent of medicating children 





In September of 2011, Congress passed the Child and Family Services Improvement and 
Innovation Act. This law requires that states applying for certain federal child welfare grants 
establish protocols for the appropriate use and monitoring of psychotropic drugs prescribed to 
children. In the GAO’s report to congress (Kutz, 2011), they indicated that compliance with 
the guidelines promulgated by the American Academy of Child and Adolescent Psychiatry 
requires obtaining informed consent for medical treatment. Unfortunately, the GAO report 
did not discuss who might be empowered to provide informed consent for foster children. In 
my personal experience, case workers and foster parents are quite intimidated by doctors and 
are reluctant to challenge a recommendation. This is consistent with Matt Salo’s (2011) 
testimony before the Carper Sub-Committee indicating that states “had to abandon an attempt 
to strengthen the hand of foster care workers in these situations, when it became clear that 
BA/BS or MSW educated workers would face significant liability issue when disagreeing 
with prescribers.” In fact, foster parents have been accused of medical neglect when they 
objected to medicating children in their care. Of course, expecting physicians to exercise 
good judgment has resulted in the extant situation. 
On December 1, 2011 SenatorTom Carper of Delaware convened the Senate Sub-
Committee on Financial Management, Government Information, Federal Services, and 
International Security. At this meeting, discussed early in this paper, the GAO announced 
plans to contact states to develop tracking systems to monitor the medicating of children in 
foster care. The federal government through National Association of Medical Directors may 
provide policies on best practice. Jim Gottstein (personal communication, 2011), of 
Psychrights, also suggests that doctors engaging in off-label prescribing for which there is 
paucity of justification in the research literature (that is, there is no medically accepted 
indication), are guilty of Medicaid fraud. Thus, the federal government can act to protect 
foster children by bringing charges of Medicaid fraud against both doctors and the 
pharmacies that fill the prescriptions.With regard to children in the general public, on August 
1, 2011, Ron Paul has introduced “The Parental Consent Act” (HR2769) which will require 
informed consent from parents for participation in mental health screening. 
Hopefully, more foster children will remain drug free given these new policies. However, 
assuming that the drugs were at least effective at sedating these children, other supports for 
foster parents will be needed. This may require more use of behavior therapy and 
psychotherapy. Evaluation of the cost effectiveness of these interventions should be made. 
Recently, Fullerton et al. (2011) noted an increase in Medicaid spending for persons with 
Major Depression which coincided with an increased reliance on atypical antipsychotics. 
Given the high cost of atypical antipsychoticssafer treatment may even be cheaper. 
REFERENCES 
Able Child Organization (2011). http://www.ablechild.org 
Akiskal, H. S., Djenderedjian, A. M., Rosenthal, R. H., and Khani, M. K. (1977). 
Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. 
American Journal of Psychiatry, 134(11), 1227-1233. 
Children in Foster Care and Excessive Medications 17
American Academy of Child and Adolescent Psychiatry. (1997). Practice parameters for the 
assessment and treatment of children and adolescents with Bipolar Disorder. Journal of 
the American Academy of Child and Adolescent Psychiatry, 36 (10 supplement),  
s157-176. 
American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition. Washington DC: Author. 
American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition-TR. Washington DC: Author. 
American Psychiatric Association, Mood disorders workgroup. (2011). Issues pertinent to a 
developmental approach to Bipolar Disorder in DSM-5. 1-6. http://www.dsm5.org 
American Psychiatric Association, Childhood and Adolescent Disorders Work Group. (2011). 
Justification for temper dysregulation disorder with dysphoria. 
http://www.dsm5.org/proposedrevision.aspx?rid=397. 
Amminger, G. P., Schafter, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. 
M., Mackinnon, A., McGorry, P. D., and Berger, G. E. (2010). Long-chain ω-3 fatty 
acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled 
trial. Archives of General Psychiatry, 67 (2), 146-154. 
Andrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., and Neale, M. C. (2011). 
Blue again; perturbational effects of antidepressants suggest monoaminergic homeostasis 
in major depression. Frontiers in Psychology, 2, Article 159, 1-24. 
Angell, M. (2005). The truth about drug companies: how they deceive us and what to do 
about it. New York: Random House. 
Angell, M. (2011, June 23). Why there is an epidemic of mental illness. New York Review of 
Books, LVIII (11), 20-22. 
Angell, M. (2011, July 14). The illusion of psychiatry. New York Review of Books, LVIII (12), 
20-22. 
Angell, M. (2011, August 18). The illusion of psychiatry’: An exchange. New York Review of 
Books, LVIII (13), 82-84. 
Anthony, J., and Scott, P. (1960). Manic-depressive psychosis in childhood. Journal of Child 
Psychology and Psychiatry, 4, 53-72. 
Baethge, C., Tondo, L., Bratti, I. M., Bschor, T., Bauer, M., Viguera, A. C., and Baldessarini, 
R. J. (2003). Prophylaxis latency and outcome in bipolar disorders. Canadian Journal of 
Psychiatry, 48 (7), 449-457. 
Baldessarini, R. J., Tondo, L., Baethge, C. L., and Bratti, I. M. (2007). Effect of treatment 
latency on response to maintenance treatment in manic-depressive disorders. Bipolar 
Disorder, 9, 386-393. 
Banu, S. H., Jahan, M., Koli, U. K., Ferdousi, S., Khan, N. Z., and Neville, B. (2007). Side 
effects of Phenobarbital and carbamazepine in childhood epilepsy: randomized controlled 
trial. British Medical Journal, 334, 1207-1213. 
Beatty, W.W., Dodge, A. M., Dodge, L. J., White, K., and Panksepp, J. (1982). Psychomotor 
stimulants, social deprivation, and play in juvenile rats. Pharmacology, Biochemistry, 
and Behavior, 16(3), 417-422. 
Bell, H.C., Pellis, S. M., Kolb, B. (2010). Juvenile peer play experience and the development 
of the orbitofrontal and medial prefrontal cortices. Behavior and Brain Research, 207(1), 
7-13. 
Jill Littrell 18
Bendz, H., Aurell, M., and Lanke, J. (2001). A historical cohort study of kidney damage in 
long-term lithium patients: continued surveillance needed. European Psychiatry, 16,  
199-206. 
Biederman, J., Faraone, S., Mick, E., Wozniak, J., Chen, L., Ouellette, C., Marrs, A., Moore, 
P., Garcia, J., Mennin, D., and Lelon, E. (1996). Attention-deficit hyperactivity disorder 
and juvenile mania: A overlooked co-morbidity? Journal of the American Academy of 
Child and Adolescent Psychiatry, 35, 997-1008. 
Biederman, J., Klein, K. R., Pine, D.S., and Klein, D. F. (1998). Resolved: mania is mistaken 
for ADHD in prepubertal children. Journal of the American Academy of Child and 
Adolescent Psychiatry, 37 (10), 1091-1096. 
Blader, J. C., and Carlson, G. A. (2007). Increased rates of bipolar disorder diagnoses among 
U.S. child, adolescent, and adult inpatients, 1996-2004. Biological Psychiatry, 62 (2), 
107-114. 
Borchers, A. T., Lee, J. L., Naguwa, S. M., Cheema, G. S., and Gershwin, M. E. (2008). 
Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmune Review, 7 (8), 
598-605. 
Breland-Noble, A.M., Elbogen, E. B., Farmer, E. M.Z., Wagner, H. R., and Burns, B. J. 
(2004). Use of psychotropic medications for youths in therapeutic foster care and group 
homes. Psychiatric Services, 55 (6), 706-708. 
Bremner, J. D. (2011). The goose that laid the golden egg: Accutane—the truth that had to be 
told. UK: Nothing but Publishing Ltd. 
Burns, B. J., Phillips, S. D., Wagner, H. R., Barth, R., Kolko, D. J., Campbell, Y., and 
Landsverk, J. (2004). Mental health need and access to mental health services by youths 
involved with child welfare: A national study. Journal of the American Academy of Child 
and Adolescent Psychology, 43, 960-970. 
Calabreses, J. R., Muzina, D. J., Kemp, D.E., Sachs, G. S., Frye, M. A., Thompson, T.R., 
Klingman, D., Reed, M. L., Hirschfeld, R. M. A., Harris, T. H., and Davis, H. K. (2006). 
Predictors of Bipolar Disorder risk among patients currently treated for major depression. 
MedGenMed 8 (3), 38. 
Calarge, C. A., Zimmerman, B., Xie, D., Kuperman, S., and Schiechte, J. A. (2010). A cross-
sectional evaluation of the effect of risperidone and selective serotonin reuptake 
inhibitors on bone mineral density in boys, Journal of Clinical Psychiatry, 7 (3), 338-
347. 
CanWestNewsService (2006, May 27). Deadly side-effects earn ADHD drugs warning. 
http:www.canada.com/topics/news/national/story.html?id=375b4d0d-75c4-4b1d-880c-
560ce953a8cb. 
Casey, D. E. (2006). Implications of the CATIE trial on treatment: extrapyramidal symptoms. 
CNS Spectrum, 11 (Suppl. 7), 25-31. 
Ceccherini-Nelli, A., Bardelllini, L., Cur, A., Guazzelli, M., Maggini, C., and Dilsaver, S. C. 
(1993). Anti-depressant withdrawal: prospective findings. American Journal of 
Psychiatry, 150, 165. 
Chambers, C. D., Hernandez-Diaz, S., Van Marter, L.J., Werier, M. M., Louik, C., Jones, 
K.L., Mitchell, A. A. (2006). Selective serotonin-reuptake inhibitors and risk of persistent 
pulmonary hypertension of the newborn. New England Journal of Medicine, 354(6),  
579-587. 
Children in Foster Care and Excessive Medications 19
Chang, K. D. (2010). Course and impact of bipolar disorder in young patients. Journal of 
Clinical Psychiatry, 71 (2), doi:10.488/JCP.8125tx7c 
Chang, K., Howe, M., Gallelli, K., and Miklowitz, D. (2006). Prevention of pediatric bipolar 
disorder: Integration of neurobiological and psychosocial processes. Annals of the New 
York Academy of Sciences, 1094, 235-247. 
Chang, K., and Kowatch, R. A. (2007). Is this child bipolar? What’s needed to improve 
diagnosis? Current Psychiatry, 6 (10) 23-33. 
Chen, Y., and Silverstone, T. (1990). Lithium and weight gain. International Clinical 
Psychopharmacology, 5(3), 217-225. 
Child and Family Services Improvement and Innovation Act, September 2011Public L. No. 
112-34, § 101(b)(2), 125 Stat. 369.  
Comer, J. S., Mojtabai, R., and Olfson, M. (2011). National trends in the antipsychotic 
treatment of psychiatric outpatients with anxiety Disorders. American Journal of 
Psychiatry 168 (10), 1057-1065. 
Correll, C. U., and Carlson, H. E. (2006). Endocrine and metabolic adverse effects of 
psychotropic medications in children and adolescents. Journal of the American Academy 
of Child and Adolescent Psychiatry, 45, 771-791. 
Coryell, W., Coryell, J., Endicott, T., Reich, N., Andreasen, N., and Keller, M. (1984). A 
family study of bipolar II disorder. British Journal of Psychiatry, 145, 49-54. 
Coryell, W., Endicott, J., Maser, J. D., Keller, M. B., Leon, A. C., and Akiskal, H. S. (1995). 
Long-term stability of polarity distinctions in the affective disorders. American Journal of 
Psychiatry, 152 (3), 385-390. 
Croen, L. A., Grether, J.K., Yoshida, C. K., Odouli, R., and Hendrick, V. (2011). 
Antidepressant use during pregnancy and childhood autism spectrum disorders. Archives 
of General Psychiatry, 68 (11), 1104-1112. 
Crystal, S., Olfson, M., Huang, C., Pincus, H., andGerhard, T. (2009). Broadened use of 
atypical antipsychotics: safety, effectiveness, and policy challenges. Health Affairs 
(Millwood), 28(5), w770-781. 
Csoka, A. B., Bahrick, A., Mehtonen, O. P. (2008). Persistent sexual dysfunction after 
discontinuation of selective serotonin reuptake inhibitors. Journal of Sexual Medicine, 5 
(1), 227-233. 
Damsa, C., Bumb, A., Bianchi-Demicheli, F., Vidailhet, P., Sterck, R., Andreoli, A., and 
Beyenburg, S. (2004). “Dopamine-dependent” side effects of selective serotonin reuptake 
inhibitors: a clinical review. Journal of Clinical Psychiatry, 65 (8), 1064-1068. 
Dawood, T., Lambert, E. A., Barton, D. A., Laude, D., Elghozi, J. L., Esler, M. D., 
Haikerwal, D., Kaye, D. M., Hotchkin, E. J., and Lambert, G. W. (2007). Specific 
serotonin reuptake inhibitors in major depressive disorder adversely affects novel cardiac 
risk. Hypertension Research, 30, 285-293. 
DelBello, M. P., Soutullo, C. A., Hendricks, W., Niemeier, R. T., McElroy, S. L., and 
Strakowski, S. M. (2001). Prior stimulant treatment in adolescents with bipolar disorder: 
Association with age of onset. Bipolar Disorders, 2, 53-57. 
Dickstein, D. P., Towbin, K. E., Van Der Veen, J. W., Rich, B. A., Brotman, M. A., Knopf, 
L., Onello, L., Pine, D. S., Leibenfult, E. (2009). Randomized double-blind placebo-
controlled trial of lithium in youth with severe mood dysregulation. Journal of Child and 
Adolescent Psychopharmacology, 19, 61-73. 
Jill Littrell 20
Domino, M. E., and Swartz, M. S. (2008). Who are the new users of antipsychotic 
medications? Psychiatric Services, 59 (5), 507-514. 
Dorph-Petersen, K-A., Pierri, J. N., Perel, J. M., Sun, Z., Sampson, A. R., and Lewis, D. A. 
(2005). The influence of chronic exposure to antispsychotic medications on brain size 
before and after tissue fixation: a comparison of haldoperiodol and olanzapine in 
macaque monkeys. Neuropsychopharmacology, 30, 1649-1661. 
dosReis, S., Zito, J. M., Safer, D.J., and Soken, K. L. (2001). Mental health services for 
youths in foster care and disabled youths. American Journal of Public Health, 91, 1094-
1099. 
dosReis, S., Yoon, Y., Rubin, D. M., Riddle, M. A., Noll, E., and Rothbard, A. (2011). 
Antipsychotic treatment among youth in foster care. Pediatrics, 128 (6), 1459-1466. 
Duffy, A., Alda, M., Hajek, T., and Grof, P. (2009). Early course of bipolar disorder in high-
risk offspring: Prospective study. British Journal of Psychiatry, 195, 457-458. 
Elliot, C. (2010). White coat, black hat: adventures on the dark side of medicine. Boston: 
Beacon Press. 
Faraone, S. V., Biederman, J., Morley, C. P., and Spencer, T. J. (2008). Effect of stimulants 
on height and weight: a review of the literature. Journal of the American Academy of 
Child and Adolescent Psychiatry, 47 (9), 994-1009. 
Fava, G. A. (2003). Can long-term treatment with antidepressant drugs worsen the course of 
depression? Journal of Clinical Psychiatry, 64(2), 123-133. 
Fava, G. A., and Offidani, E. (2011). The mechanisms of tolerance in antidepressant action. 
Progress in Neuropsychopharmacology and Biological Psychiatry, 35 (7), 1593-1602. 
Fava, M. (2000). Weight gain and antidepressants. Journal of Clinical Psychiatry, 61 
(Supplement 11), 37-41. 
Fava, M. (2006). A cross-sectional study of the prevalence of cognitive and physical 
symptoms during long-term antidepressant treatment. Journal of Clinical Psychiatry, 67, 
1754-1759. 
Frances, A. (2009, June 26). A warning sign on the road to the DSM-V: beware of its 
unintended consequences. Psychiatric Times, 26 (8). 
Frances, A. (2010a, March 1). It’s not too late to save ‘normal’. Los Angeles 
Times.http://articles.latimes.com/2010/mar/01/opinion/la-oe-frances1-201mar01. 
Frances, A. (2010b, July 6). Normality is an endangered species: Psychiatric fads and 
overdiagnosis. Psychiatric Times. http://www.psychiatrictimes.com/display/article/ 
10168/1598676 
Frances, A. (2011a, November 11). DSM-5: living document or dead on arrival? Psychiatric 
Times. http://www.psychiatrictimes.com/blog/dsm-5/content/article/10168/1989691 
Frances, A. (2011b, November 10) The user’s revolt against DSM-5: will it work? 
Psychiatric Times. http://www.psychiatrictimes.com/blog/dsm-5/content/article/10168/ 
1988483 
Frances, A. (2011c, November 5). Allen Frances: why psychiatrists should sign the petition to 
reform DSM 5: the fight for the future of psychiatry. http:societyforhumanistic 
psyhchology.blogspot.com/2011/11/allen-frances-why-psychiatrists-should-sign-the-
petition. 
Fullerton, C. A., Busch, A. B., Normand, S-T. T., McGuire, T. G., and Epstein, A. M. (2011). 
Ten-year trends in quality of care and spending for depression: 1996 through 2005. 
Archives of General Psychiatry, 66 (12), 1218-1226. 
Children in Foster Care and Excessive Medications 21
Galliford, J., and Game, D. S. (2009). Modern renal transplantation: present challenges and 
future prospects. Postgraduate Medical Journal, 85, 91-101. 
Geller, B., Cooper, T. B., Zimerman, B., Frazier, J., Williams, M., Heath, J., and Warner, K. 
(1998). Lithium for prepubertal depressed children with family history predictors of 
future bipolarity: a double-blind, placebo-controlled study. Journal of Affective 
Disorders, 51, 165-175. 
Gentile, S. (2011). Drug treatment for mood disorders in pregnancy. Current Opinion in 
Psychiatry, 24(1), 34-40. 
Ghaemi, S. N. (2008). Practical guides in psychiatry: mood disorders, 2nd ed. New York: 
Lippincott, Williams, and Wilkins. 
Ghaemi, S. N., Hsu, D. J., Soldani, F., and Goodwin, F. K. (2003). Antidepressants in bipolar 
disorder: The case for caution. Bipolar Disorders, 5, 421-433. 
Gleason, M. M., Egger, H.L., Emslie, G. J., Greenhill, L. L., Kowatch, R. A., Lieberman, A. 
F., Luby, J.L., Owens, J., Schahill, L. D., Scheeringa, M. S., Stafford, B., Wise, B., and 
Zeanah, C.H. (2007). Pharmacological treatment for very young children: Context and 
guidelines. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 
1532-1572. 
Goldberg, J. F., Harrow, M., and Whiteside, J. E. (2001). Risk for bipolar illness in patients 
initially hospitalized for unipolar depression. American Journal of Psychiatry, 15, 1265-
1270. 
Goldstein, T. R., Frye, M. A., Denicoff, K. D., Smith-Jackson, E., Leverich, G. S., Bryan, A. 
L., Ali, S. O. and Post, R. M. (1999). Antidepressant discontinuation-related mania: 
critical prospective observation and theoretical implications in bipolar disorder. Journal 
of Clinical Psychiatry, 60, 563-567. 
Goodman, W. K., Murphy, T. K., and Storch, E. A. (2007). Risk of adverse behavioral effects 
with pediatric use of antidepressants. Psychopharmacology, 191, 87-96. 
Goodwin F. K., and Jamison, K. R. (2007). Manic-depressive illness: bipolar disorders and 
recurrent depression, 2nd ed. New York: Oxford Press. 
Grassley, C.E. (2010, June 24). Ghostwriting in Medical Literature, Minority Staff Report, 
111th Congress; U.S. Senate Committee on Finance. http://www.grassley.senate.gov/ 
about/upload/Senator-Grassley-Report.pdf 
Greenberg, G. (2010, December 10). Inside the battle to define mental illness [Web log post]. 
Retrieved from www.wired.com /magazine/2010/12/ff_dsmv/all/1 on 3/1/11  
Haddad, P. (1997). New antidepressants and the discontinuation syndrome. Journal of 
Clinical Psychiatry, 58, Supplement 7, 17-21.  
Hagino, O. R., Weller, E. B., Weller, R. A., Washing, D., Fristad, M. A., Kontras, S. B. 
(1995). Untoward effects of lithium treatment in children aged four through six years. 
Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1584-1590. 
Hamer, M., Batty, G. D., Marmot, M. G., Singh-Manoux, A., and Kivimäki, M. (2011). Anti-
depressant medication use and C-reactive protein: results from two population-based 
studies. Brain, Behavior, and Immunity, 25, 168-173. 
Harris, G., and Carey, B. (2008a, June 8). Researchers fail to reveal full drug pay: Possible 
conflicts seen in Child Psychiatry, New York Times. Retried October 3, 2008 from 
http://www.nytimes.com 
Harris, G., and Carey, B. (2008b, July 12). Psychiatric Association faces Senate scrutiny over 
drug industry ties. New York Times, A 13. 
Jill Littrell 22
Harrow, M., Goldberg, J. F., Grossman, L. S., and Meltzer, H. Y. (1990). Outcome in manic 
disorders. Archives of General Psychiatry, 47 (7), 665-671. 
Hart, C. L., Ksir, C., and Ray, O. (2009). Drugs, society, and human behavior, 13th edition. 
New York: McGraw Hill. 
Henin, A., Mick, E., Biederman, J., Fried, R., Hirshfeld-Becker, D. R., Micco, J. A., Miller, 
K. G., Rycyna, C.C., and Wozniak, J. (2009). Is psychopharmacologic treatment 
associated with neuropsychological deficits in bipolar youth? Journal of Clinical 
Psychiatry, 70 (8), 1178-1185. 
Ho, B-C., Andreasen, N. C., Ziebell, S., Pierson,m R., and Magnotta, V. (2011). Long-term 
antipsychotic treatment and brain volume. Archives of General Psychiatry, 68 (2),  
128-137. 
Insel, T. R. (2009). Disruptive insights in psychiatry: transforming a clinical discipline. 
Journal of Clinical Investigation. 119 (4), 700-705. 
Isojarvi, JIT, Laatikainen, T. J., Pakarienen, A. J., Juntunen K.T.S., Myllyla, V. V. (1993). 
Polycystic ovaries and hyperandrogenism in women taking valporate for epilepsy. New 
England Journal of Medicine, 329, 1383-1388. 
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Maser, J., Rice, J. A., Solomon, D. 
A., and Keller, M. B. (2003). The comparative clinical phenotype and long term 
longitudinal episode course of bipolar I and II: a prospective, comparative, longitudinal 
study. Journal of Affective Disorders, 73, 19-32. 
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. 
C., Rice, J. A., and Keller, M. B. (2002). The long-term natural history of the weekly 
symptomatic status of Bipolar I Disorder. Archives of General Psychiatry, 59, 530-537. 
Jureidini, J. JN., Doecke, C. J., Mansfield, P. R., Haby, M. M., Menkes, D. B., and Tonkin, A. 
L. (2004). Efficacy and safety of antidepressants for children and adolescents. British 
Medical Journal, 328, 879-883. 
Kemp, A. H., Quintana, D. S., Gray, M. A., Felmingham, K. L., Brown, K., andGatt, J. 
(2010). Impact of depression and antidepressant treatment on heart rate variability: a 
review and meta-analysis. Biological Psychiatry, 67, 1067-1074. 
Kiecolt-Glaser, J. K. (2010). Stress, food, and inflammation: psychoneuroimmunology and 
nutrition at the cutting edge. Psychosomatic Medicine, 72(4), 365-369. 
Kiecolt-Glaser, J. K., Belury, M. A., Andridge, R., Malarkey, W. B., and Glaser, R. (2011). 
Omega-3 supplementation lowers inflammation and anxiety in medical students: a 
randomized controlled trial. Brain, Behavior,and Immunity, 25(8), 1725-1734. 
Kirsch, I. (2010). The emperor’s new drugs: exploding the antidepressant myth. New York: 
Basic Books. 
Kirsch, I., Moore, T. J., Scoboria, A., and Nicholls, S. S. (2002). The emperor’s new drugs: 
an analysis of antidepressant medication data submitted to the U.S. Food and Drug 
Administration. Prevention and Treatment, Vol5, Article 2, Copyright by American 
Psychological Association. 
Kivimäjum N., Hamer, M., Batty, G. D., Geddes, J. R., Tabak, A. G., Pentti, J., Virtanen, M., 
and Vahtera, J. (2010). Antidepressant medication use, weight gain, and risk of Type 2 
diabetes. Diabetes Care, 33 (12), 2611-2616.  
Konopaske, G. T., Dorph-Petersen, K-A., Pierri, J. N., Wu, Q., Sampson, A. R., and Lewis, 
D. A. (2007). Effect of chronic exposure to antipsychotic medication on cell numbers in 
the parietal cortex of the macaque monkeys. Neuropsychopharmacology, 32, 1216-1223. 
Children in Foster Care and Excessive Medications 23
Konopaske, G. T., Dorph-Petersen, K-A., Sweet, R. A., Pierri, J. N., Zhang, W., Sampson, A. 
R., and Lewis, D. A. (2008). Effect of chronic antipsychotic exposure on astrocyte and 
oligodendrocyte numbers in macaque monkeys. Biological Psychiatry, 63, 759-765. 
Kutz, G. D. (2011) United States Accountability Office Testimony before the Subcommittee 
on Federal Financial Management, Government Information, Federal Services, and 
International Security, Committee on Homeland Security and Governmental Affairs, U.S. 
Senate. December 1, 2011; Gregory D. Kutz, Director Forensic Audits and Investigative 
Service. 
Lejoyeux, M., and Adés, J. (1997). Antidepressant discontinuation: a review of the literature. 
Journal of Clinical Psychiatry, 58 (Supplement 7), 11-15. 
Leslie, L., Kelleher, K., Burns, B., Landsverk, J., and Rolls, J. (2003). Foster care and 
Medicaid managed care. Child Welfare League of America, 82(3), 367-392. 
Leverich, G. S., Alshuler, L. L., Frye, M. A., Suppes, T., McElory, S. L., Keck, P. E., Kupka, 
R. W., Denicoff, K. D., Nolen, W. A., Grunze, H., Martinez, M. I., and Post, R. M. 
(2006). Risk of switch in mood polarity to hypomania or mania in patients with bipolar 
depression during acute and continuation trials of venlafaxine, sertraline, and bupropion 
as adjuncts to mood stabilizers. American Journal of Psychiatry, 163, 232-239. 
Littrell, J. (1994). Relationship between time since reuptake-blocker antidepressant 
discontinuation and relapse. Experimental and Clinical Psychopharmacology, 2 (1),  
82-94.  
Littrell, J. and Lyons, P. (2010a). Pediatric Bipolar Disorder: Part I—Is it related to classical 
Bipolar? Children and Youth Services Review, 32(7), 945-964. 
Littrell, J., and Lyons, P. (2010b) . Pediatric Bipolar Disorder: An issue for child welfare. 
Children and Youth Services Review, 32(7), 965-973. 
Loranger, A., and Levine, P. (1978). Age at onset of bipolar affective illness. Archives of 
General Psychiatry, 35, 1345-1348. 
Loring, D. W., and Meador, K. J. (2004). Cognitive side effects of antiepileptic drugs in 
children. Neurology, 62, 872-877. 
Manschreck, T. C., and Boshes, R. A. (2007). The CATIE schizophrenia trail: results, impact, 
and controversy. Harvard Review of Psychiatry, 15(5), 245-258. 
Markowitz, G. S., Radhakrishnan, J., Kambham, N., Valeri, A. M., Hines, W. H., and 
D’Agatti, V.D. (2000). Lithium nephrotoxicity: A progressive combined glomerular and 
tubulointerstitial nephropathy. Journal of the American Society of Nephrology, 11, 1439-
1448. 
Marroun, H.E., Jaddoe, V.W.V., Mudziak, J. J., Roza, S. J., Steegers, E. A. P., Hofman, A., 
Vurhulst, F. C., White, T. J.H., Stricker, B. H. C., and Tiemeier, H. (2012). Maternal use 
of Selective Serotonin Reuptake inhibitors, fetal growth, and risk of adverse birth 
outcomes. Archives of General Psychiatry, 69 (7), 706-714. 
Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., andCroudace, T., (2005). 
Association between duration of untreated psychosis and outcome in cohorts of first-
episode patients: a systematic review. Archives of General Psychiatry, 62 (9), 975-983. 
Marshall, M., and Rathbone, J. (2011a). Early intervention for psychosis. The Cochrane Data 
Base Systematic Reviews, 6, CD004187. 
Marshall, M., and Rathbone, J. (2011b). Early intervention for psychosis. Schizophrenia 
Bulletin, 37 (6), 1111-1114. 
Jill Littrell 24
Martin, A., Young, C., Leckman, J. P., Mukonoweschuro, C., Rosenheck, R., and Leslie, D. 
(2004). Age effects in antidepressant-induced manic conversion. Archives of Pediatric 
Adolescent Medicine, 158(8), 773-780. 
Medicaid Medical Directors Learning Network and Rutgers Center for Education and 
Research on Mental Health Therapeutics. (2010, July) Antipsychotic Medication Use in 
Medicaid Children and Adolescents: Report and Resource Guide from a 16-state study, 
MMDLN/Rutgers CERTs, Publication 1 http://rci.rutgers.edu/~cseap/ 
MMDLNAPKIDS/Antipsychotic_Use_in_Medicaid_Children_Report_and_Resource_G
uide_Final.pdf 
McCabe, C.,Mishor, Z., Cowen, P. J., and Harmer, C. J. (2010). Diminished neural 
processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor 
treatment. Biological Psychiatry, 67 (5), 439-445. 
McGrath, P. J., Stewart, J. W., Tricamo, E., Nunes, E. N., and Quitkin, F. M. (1993). 
Paradoxical mood shifts to euthytmia or hypomania upon withdrawal of antidepressant 
agents. Journal of Clinical Psychopharmacology, 13(3), 224-225. 
Miklic, S., Juric, D. M., and Carman-Krzan, M. (2004). Differences in the regulation of bdnf 
and ngf synthesis in cultured neonatal rat astrocytes. International Journal of 
Developmental Neuroscience, 22, 119-130. 
Molina, B.S.G., Hinshaw, S.P., Swanson, J. M., Arnold, L.E., Vitiello, B., Jensen, P. S., 
Epstein, J. N., Hoza, B., Hechtman, L., Abikoff, H. W., Elliot, G. R., Greenhill, L. L., 
Newcorn, J.H., Well, K. C., Wigal, T., Gibbons, R. D., Hur, K., Houck, P.S.and MTA 
Cooperative Group. (2009). The MTA at 8 years: Prospective follow-up of children 
treated for combined type ADHD in a Multisite Study. Journal of the American Academy 
of Child and Adolescent Psychiatry, 48(5), 484-500. 
Miller, D. D., EcVoy, J.P. Davis, S. M.< Caroff, S. N., Saltz, B. L., Chakos, M. H., Swartz, 
M. S., Keefe, R. S., Rosenheck, R. A., Stroup, T. S., and Lieberman, J. A. (2005). 
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE 
schizophrenia trail. Schizophrenia Research, 80(1), 33-43. 
Moncrieff, J. (2003). Is psychiatry for sale? Maudsley discussion paper. Available as booklet 
from the institute of psychiatry sarah.smith@iop.kcl.ac.uk. 
Moreno, C., Laje, G., Blanco, C., Jiang, H., Schmidt, A. B., and Olfson, M. (2007). National 
trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Archives of 
General Psychiatry, 64 (9), 1032-1039. 
Murphy, K. (2012). Janeway’s Immunobiology. New York: Garland Science. 
Nemeroff, C. B. (2001). Progress in the battle with the black dog: Advances in the treatment 
of depression. American Journal of Psychiatry, 158 (10), 1555-1557. 
Pachet, A. K., and Wisniewski, A. M. (2003). The effects of lithium on cognition: an updated 
review. Psychopharmacology, 170, 225-234. 
Pato, M. T., Zohar-Kadouch, R., Zohar, J., and Murphy, D. L. (1988). Return of symptoms 
after discontinuation of clomipramine in patients with obsessive-compulsive disorder. 
American Journal of Psychiatry, 145, 1521-1525. 
Perkins, D. D., Gu, H., Boteva, K., Lieberman, J. A. (2005). Relationship between duration of 
untreated psychosis and outcome in first-episode schizophrenia: a critical review and 
meta-analysis. American Journal of Psychiatry, 162 (10), 1785-1804. 
Physicians’ desk reference, (66 edition). (2012). Montvale, NJ: PDR Network. 
Children in Foster Care and Excessive Medications 25
Post, R. (2004). Neurobiology of seizures and behavioral abnormalities. Epilepsia, 45, 
(Suppl. 2), 5-14. 
Post, R. M. (2007). Kindling and sensitization as models for affective episode recurrence, 
cyclicity, and tolerance phenomena. Neuroscience and Biobehavioral Reviews, 31, 858-
873. 
Post, R. M., Denicoff, K. D., Leverich, G. S., Altschuler, L. L., Frye, M. A., Suppes, T. M., 
Rush, A. J., Keck, P. E., McElroy, S. L., Luckenbaugh, D. A., Pollio, C., Kupka, R., and 
Nolen, W. A. (2003). Morbidity in 258 bipolar outpatients followed for 1 year with daily 
prospective ratings on the NIMH life chart method. Journal of Clinical Psychiatry, 64 
(6), 680-690. 
Postma, T., Krupp, E., Li, X. L., Post, R. M., and Weiss, S.R. (2000). Lamotrigine treatment 
during amygdala-kindled seizure development fails to inhibit seizures and diminishes 
subsequent anticonvulsant efficacy. Epilepsia, 41(12), 1514-1521. 
Presne, C., Fakhouri, F., Noёl, L-H., Stengel, B., Even, C., Kreis, H., Mignon, F., and 
Grϋnfeld, J-P. (2003). Lithium-induced nephropathy: Rate of progression and prognostic 
factors. Kidney International, 64, 585-592. 
Psychiatric News Alert (2011, July 21). FDA orders new warning on Seroquel label. 
http://alert.psychiatricnews.org/2011/03/fda-order-new-warning-on-seroquel.html 
Psychrights (2011). http:psychrights.org/index.htm. 
Raeder, M. B., Bjelland, I., Emil Vollset, S., and Steen, V. M. (2006). Obesity, dyslipidemia, 
and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. 
Journal of Clinical Psychiatry, 67 (2), 1947-1982. 
Raghavan, R., and McMillen, J. C. (2007). Patterns of psychotropic medication use among 
older adolescents in foster care. Academy Health Annual Research Meeting. Orlando, FL. 
Raghavan, R., Zima, B. T., Andersen, R. M., Leibowitz, A. A., Schuster, M. A., and 
Landsverk, J. (2005). Psychotropic medication use in a National Probability sample of 
children in the child welfare system. Journal of Child and Adolescent 
Psychopharmacology, 15, 97-106.  
Reinblatt, S. P., dosReis, S., Walkup, J. T., and Riddle, M. A. (2009). Activation adverse 
events induced by selective serotonin reuptake inhibitor fluvoxamine in children and 
adolescents. Journal of Child and Adolescent Psychopharmacology, 19(2), 119-136. 
Rennie, T. A. C. (1942). Prognosis in manic-depressive psychosis. American Journal of 
Psychiatry, 98, 801-814. 
Rohde, P., Silva, S. G., Tonev, S. T., Kennard, B. D., Vitiello, B., Kratochvil, C. J., Reinecke, 
M. A., Curry, J. F., Simons, A. D., and March, J. S. (2008). Achievement and 
maintenance of sustained response during the TADS continuation and maintenance 
therapy. Archives of General Psychiatry, 65(4), 447-455. 
Rosen, R. C., Lane, R. M., and Menza, M. (1999). Effects of SSRIs on sexual function: a 
critical review. Journal of Clinical Psychopharmacology, 19 (1), 67-85. 
Rubin, R. R., Ma, Y., Peyrot, M., Marrero, D. G., Price, D.W., Barrett-Connor, E., Knowler, 
W. C. (2010). Antidepressant medicine use and risk of developing diabetes during the 
diabetes prevention program and diabetes prevention program outcome study. Diabetes 
Care, 33 (12), 2549-2551. 
Safer, D. J. (2004). A comparison of risperidone-induced weight gain across the life span. 
Journal of Clinical Psychopharmacology, 24, 429-436. 
Jill Littrell 26
Salo, M. (2011, December 1). The financial and societal cost of medicating America’s foster 
children. Testimony of Executive Director for the National Association of Medicaid 
Directors before the Senate Homeland Security and Government Affairs Committee. 
http://hsgac.senate.gov/public/index.cfm?FuseAction=Hearings.HearingandHearing_Ib=
9fc194de-2a7c-4417-8f2b-6b90cadacede 
Samuels, B. (2011, December 1). Testimony of the Commissioner form Administration of 
Children, Youth and Families and Administration of Children and Families, U.S. 
Department of Health and Human Services before the Senate Homeland Security and 
Government Affairs Committee.http://hsgac.senate.gov/public/index.cfm?Fuse 
Action=Hearings.HearingandHearing_Ib=9fc194de-2a7c-4417-8f2b-6b90cadacede 
Schwartz, M., and Schechter, R. (2011). Systemic inflammatory cells fight off 
neurodegenerative disease. Nature Reviews: Neurology, 6, 405-410. 
Sikich, L., Hamer, R. M., Bashford, R. A., Sheitman, B. B., and Lieberman, J. A. (2004). A 
pilot study of risperidone, olanzapine and haloperidol in psychotic youth: A double-blind, 
randomized, 8-week trial. Neuropsychopharmacology, 29, 133-145. 
Silva, R. R., Campbell, M., Golden, R. R., Small, A. M., Pataki, C. S., and Rosenberg, C. R. 
(1992). Side effects associated with lithium and placebo administration in aggressive 
children. Psychopharmacology Bulletin, 28 (3), 319-326. 
Sinaikin, P. (2010). Psychiatryland. New York: iUniverse, Inc. 
Soetens, E., E’Hooge, R., and Hueting, J.E. (1993). Amphetamine enhances human-memory 
consolidation. Neuroscience Letter, 161 (1), 9-12. 
Sostek, A. J., Buchsbaum, M. S., and Rapoport, J. L. (1980). Effects of amphetamine on 
vigilance performance in normal and hyperactive children. Journal of Abnormal Child 
Psychology, 8(4), 491-500. 
Spetie, L., and Arnold, L. E. (2007). Ethical issues in child psychopharmacology research and 
practice: Emphasis on preschoolers. Psychopharmacology, 191, 15-26. 
Stahmer, A. C., Leslie, L. K., Hurlburt, M. S., Barth, R., Webb, M. B., Landsverk, J.A. and 
Zhang, J. (2005). Developmental and behavioral needs and service use for young children 
in child welfare. Pediatrics, 116, 891-900. 
Stoukides, J.A., and Stoukides, C. A. (1991). Extrapyramidal symptoms upon discontinuation 
of fluoxetine. American Journal of Psychiatry, 148, 1263. 
Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, 
S., Harriett, A.E., and Wang, Y. (2005). Remission rates following antidepressant therapy 
with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data 
from 7 randomized controlled trials. Journal of Clinical Psychiatry, 66 (8), 974-981. 
Thompson, A., Nelson, B., and Yung, A. (2011). Predictive validity of clinical variables in 
the “at risk” for psychosis population: international comparison with results from the 
North American Prodrome Longitudinal Study. Schizophrenia Research, 126 (1-3),  
51-57. 
Tohen, M., Kryzhanovskaya, L, Carlson, G., DelBello, M., Wozniak, J., Kowatch, R., 
Wagner, K., Findling, R., Lin, D., Robertson-Plouch, C., Xu, W., Dittmann, R. W., and 
Biederman, J. (2007). Olanzapine versus placebo in the treatment of adolescents with 
bipolar mania. American Journal of Psychiatry, 164, 1547-1556. 
Tranter, R., O’Donovan, C., Chandarana, P., and Kennedy, S. (2002). Prevalence and 
outcome of partial remission in depression. Journal of Psychiatry and Neuroscience, 27 
(4), 241-247. 
Children in Foster Care and Excessive Medications 27
TADS (2007). The Treatment for Adolescents with Depression Study. Archives of General 
Psychiatry, 64(10), 1132-1144. 
TADS (2009). The Treatment for Adolescents with Depression Study(TADS): outcomes over 
1 year naturalistic follow-up. American Journal of Psychiatry, 166, 1141-1149. 
Tyre, P. (2004, December). Battling the effects of war. Newsweek. Retrieved September 14, 
2008. from http://www.newsweek.com/id/5598. 
Udachina, A., and Mansell, W. (2007). Cross-validation of the mood disorders questionnaire, 
the internal state, and the hypomanic personality scale. Personality and Individual 
Differences, 42, 1539-1549. 
Udechucku, A., Nguyen, T., Hill, R, and Szego, K. (2010). Antidepressants in pregnancy: a 
systemic review. Australian and New Zealand Journal of Psychiatry, 44(11), 978-996. 
U.S. Food and Drug Administration (2007). Antidepressant use in children and adults: 
Revisions to medication guide. http://www.fda.gov/Drugs/DrugSafety/Informationby 
DrugClass/ucm096273.htm retrieved on 3/1/11. 
U.S. Food and Drug Administration (2008, January 31). Information on carbamazepine 
(marketed as carbatrol, equetro, tegretol, and generics) with FDA alerts. 
http:www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor 
PatientsandProviders/ucm10784.htm retrieved on 3/1/11. 
U.S. Food and Drug Administration (2009, January). Highlights of prescribing information. 
http://www.fda./downloads./AdvisoryCommittees/CommiteesMeetingMaterials/Pediatric 
Advisory/Committee/UCM166792.pdf retrieved on 12/22/11. 
U.S. Department of Health and Human Services (2007). The AFCARS Report. Retrieved on 
September 12, 2008, from http://www.acf.dhhs.gov/programs/cb/stats_research/ 
alcars/tar/report13.htm 
Vieta, E., and Suppes, T. (2008). Bipolar II disorder: Arguments for and against a distinct 
diagnostic entity. Bipolar Disorders, 10, 163-178. 
Watch List (Producer) and Shoshana Guy (Producer). (2011-January 7). The Medication of 
Children in Foster Care (DVD). www.pbs.org/wnet/need-to-know/health/video-the-
watch-list-the-medication-of-foster-children/6232 
Weintrob, N., Cohen, D., Klipper-Aurbach, Y., Zadik, Z., and Dickerman, Z. (2002). 
Decreased growth during therapy with selective serotonin reuptake inhibitors. Archives 
of Pediatric and Adolescnet Medicine, 156 (7), 696-701. 
Weiss, S. R.B., Clark, M., Rosen, J. R., Smith, M. A., and Post, R. M. (1995). Contingent 
tolerance in the anticonvulsant effects of carbamazepine: Relationship to loss of 
endogenous adaptive mechanisms. Brain Research Reviews, 20, 305-325. 
Whitaker, R. (2010). Anatomy of an epidemic. New York: Crown Publishers. 
Wicki, W., and Angst, J. (1991). The Zurich study: X. Hypomania in a 28-30 year-old cohort. 
European Archives of Psychiatry and Clinical Neuroscience, 240, 339-348. 
Winokur, G., Clayton, P. J., and Reich, T. (1969). Manic Depressive Illness. St. Louis: C.V. 
Mosby Company. 
Winocur, G., Coryell, W., Akiskal, H.S., Endicott, J., Keller, M., and Mueller, T. (1994). 
Manic-depressive (bipolar) disorder: the course in light of a prospective ten-year follow-
up of 131 patients. Acta Psychiatrica Scandanavia, 89 (2), 102-110. 
Woods, S. W., Martin, A., Spector, S. G., and McGlashan, T. H. (2002). Effects of 
development on olanzapine-associated adverse events. Journal of the American Academy 
of Child and Adolescent Psychiatry, 41 (12), 1439-1446. 
Jill Littrell 28
Wozniak, J., Biederman, J., Mundy, E., Mennin, D., and Faraone, S. V. (1995). A pilot family 
study of childhood-onset mania. Journal of the American Academy of Child and 
Adolescent Psychiatry, 34, 1577-1583. 
Zarate, C. A., Tohen, M., Land, M., and Cavanagh, S. (2000). Functional impairment and 
cognition in bipolar disorder. Psychiatric Quarterly, 71 (4), 309-329. 
Zhang, H., Du, M., and Zhuang, S. (2010). Impact of long-term treatment of methylphenidate 
on height and weight of school age children with ADHD. Neuropediatrics, 41 (2), 55-59. 
Ziv, Y., and Schwartz, M. (2008). Immune-based regulation of adult neurogenesis: 
Implications for learning and memory. Brain, Behavior, and Immunity, 22, 167-176. 
 
 
 
